Abstract
Pretargeting techniques using the avidin-biotin system have shown encouraging results in both diagnostic and therapeutic clinical trials. It has been shown that in cancer therapy the ideal agent to be used for pretargeting should have a plasma half-life longer than avidin and lower immunogenicity than streptavidin in order for these procedures to be applied safely and repeatedly in patients. We prepared a recombinant form of avidin with no carbohydrates and avidins, biochemically modified either by decreasing the positive charges with succinic anhydride or by linking polyethylene glycol (PEG) at three different molar ratios and evaluated their in vivo behaviour after i.p. administration in mice. The succinylation and PEGylation of avidin increased the plasma half-life proportionally to the degree of protein modification. The procedures, however, affected the biotin binding to some extent. The biodistribution studies showed that, for all six time points (ranging from 20 min to 18 h post-injection), the liver and kidney to blood ratios were lower for PEGylated avidins than native, recombinant and succinyl avidin. Recombinant and low PEGylated avidin evoked an immune response in all mice after at least three injections. Native, recombinant and succinyl avidins showed higher serum titres than PEGylated avidins. In conclusion, the conjugation of avidin to PEG chains (n = 7) originates a compound with a suitable blood clearance, low immunogenicity and concurrent low cross-reactivity with avidin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chinol, M., Casalini, P., Maggiolo, M. et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 78, 189–197 (1998). https://doi.org/10.1038/bjc.1998.463
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.463
This article is cited by
-
Surface loading of nanoparticles on engineered or natural erythrocytes for prolonged circulation time: strategies and applications
Acta Pharmacologica Sinica (2021)
-
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
Scientific Reports (2020)
-
A versatile method for the preparation of particle-loaded microbubbles for multimodality imaging and targeted drug delivery
Drug Delivery and Translational Research (2018)
-
A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors
Nano Research (2015)
-
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
Nature Reviews Rheumatology (2013)